114 related articles for article (PubMed ID: 20949248)
1. New perspectives: role of sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2010; 161(5):475-82. PubMed ID: 20949248
[TBL] [Abstract][Full Text] [Related]
2. New perspectives: role of Sunitinib in breast cancer.
Fratto ME; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G
Clin Ter; 2011; 162(3):251-7. PubMed ID: 21717054
[TBL] [Abstract][Full Text] [Related]
3. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Polyzos A
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: bridging present and future cancer treatment.
Grimaldi AM; Guida T; D'Attino R; Perrotta E; Otero M; Masala A; Cartenì G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi31-4. PubMed ID: 17591828
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Papaetis GS; Syrigos KN
BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib malate.
Izzedine H; Buhaescu I; Rixe O; Deray G
Cancer Chemother Pharmacol; 2007 Aug; 60(3):357-64. PubMed ID: 17136543
[TBL] [Abstract][Full Text] [Related]
8. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Cabebe E; Wakelee H
Drugs Today (Barc); 2006 Jun; 42(6):387-98. PubMed ID: 16845442
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in solid tumors.
Gan HK; Seruga B; Knox JJ
Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
14. The potential role of sunitinib in gastrointestinal cancers other than GIST.
Grávalos C; Grande E; Gasent JM
Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
Motzer RJ; Hoosen S; Bello CL; Christensen JG
Expert Opin Investig Drugs; 2006 May; 15(5):553-61. PubMed ID: 16634693
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in the treatment of advanced solid tumors.
Imbulgoda A; Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2014; 201():165-84. PubMed ID: 24756791
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2007 May; 356(2):323-8. PubMed ID: 17367763
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
